Because AD associated with PSEN1 mutations has a presumed single-cause etiology and the average age at death is under 60 years, any comorbidities in this setting may be considered as at least partially secondary to the causative AD mechanisms rather than aging, and thus indicate whether effective AD therapeutics may also be effective for comorbidities. This evidence concerns the gene PSEN1 and Alzheimer disease.